[SW3-3] Muse細胞を用いた修復医療の実現へ
Muse cells are naturally existing, non-tumorigenic reparative endogenous stem cells identified by SSEA-3, a surface marker for pluripotent stem cells. They have very unique profiles; they home to damaged site in order to regenerate tissue and differentiate into nearly all types of cells in the body, according to ‘the logic of the site’ where they are integrated. Furthermore, because Muse cells have an immunomodulatory system, Muse cells derived from allogenic donor can be directly administered to patients without HLA-matching or long term-immunosuppression therapy.
Life Science Institute, Inc. (LSII), a member of Mitsubishi Chemical Holdings Group, aims to put “Reparative Medicine” into practical use through research and development of a human allogenic Muse cell-based products, CL2020. Furthermore, LSII established the manufacturing processes and quality control test methods. This will enable to produce CL2020 of a guaranteed quality and quantity. The clinical trials with intravenous drip of CL2020 are already being conducted in myocardial infarction, stroke, epidermolysis bullosa and spinal cord injury. CL2020 has a great potential for good efficacy and safety in various diseases via i.v. drip without immunosuppressant, that is special features as an ideal cell therapy.
We believe that CL2020 will be an innovative treatment using a natural repair system as “Reparative Medicine”.
Life Science Institute, Inc. (LSII), a member of Mitsubishi Chemical Holdings Group, aims to put “Reparative Medicine” into practical use through research and development of a human allogenic Muse cell-based products, CL2020. Furthermore, LSII established the manufacturing processes and quality control test methods. This will enable to produce CL2020 of a guaranteed quality and quantity. The clinical trials with intravenous drip of CL2020 are already being conducted in myocardial infarction, stroke, epidermolysis bullosa and spinal cord injury. CL2020 has a great potential for good efficacy and safety in various diseases via i.v. drip without immunosuppressant, that is special features as an ideal cell therapy.
We believe that CL2020 will be an innovative treatment using a natural repair system as “Reparative Medicine”.